Pembrolizumab and Lenvatinib Trial for Unresectable Cutaneous Angiosarcoma Initiated
A clinical trial is underway to evaluate the efficacy of pembrolizumab and lenvatinib in patients with unresectable cutaneous angiosarcoma.
Therapeutic Area
Therapeutic area intelligence for Cutaneous Angiosarcoma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.